gvtcx

Oncology Generic Medicines - Additions

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£17,077,727
Statuscomplete
Category (CPV) 33600000
RegionScotland
Deadline13 Apr 2021
Procedureopen
OCIDocds-h6vhtk-029adf

Awards (17)

This procurement was awarded to 16 suppliers. Values shown are per-award; the notice total is £17,077,727.

SupplierValueDateStatus
Accord Healthcare Ltd shared · · ·
Aspen Pharma Ireland Ltd shared · · ·
Bristol-Myers Squibb Pharmaceuticals shared · · ·
Celgene Ltd shared · · active
Dr Reddy's Laboratories (UK) Ltd shared · · active
Glenmark Pharmaceuticals Europe Ltd shared · · ·
Ipsen Limited shared · · ·
Napp Pharmaceuticals shared · · ·
Novartis Pharmaceuticals UK Ltd shared · · ·
Pfizer Ltd shared · · ·
Pierre Fabre Ltd shared · · active
Sandoz Ltd shared · · ·
Teva UK Limited shared · · ·
Thornton & Ross Ltd shared · · ·
Tillomed Laboratories ltd shared · · ·
Zentiva Pharma UK Ltd shared · · active
not named shared · · unsuccessful

description

Supply of oncology generic medicines to NHS Scotland

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
11 Mar 2021 Contract notice (F02) Earlier regulations 004974-2021
22 Jun 2021 Contract award notice (F03) Earlier regulations 014174-2021

more from The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.